Quinazoline Crystal Forms for Brain-Penetrant ErbB2 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-ErbB2 agents, such as monoclonal antibodies, antibody drug conjugates, and tyrosine kinase inhibitors, lack central nervous system penetrability, limiting their efficacy in treating ErbB2 positive breast cancer with brain metastases.
Innovation Solution
Development of new crystalline and amorphous forms of the quinazoline derivative (R)-N-(4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-3-methylphenyl)-5-((3,3-difluoro-1-methylpiperidin-4-yl)oxy)-6-methoxyquinazolin-4-amine, including complexes with pharmaceutically acceptable acids and salts, which exhibit improved brain penetration and selectivity against ErbB2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-ErbB2 agents (monoclonal antibodies, ADCs, TKIs) are used, then ErbB2 inhibition is achieved, but central nervous system penetrability is insufficient
Solution Approach 1:
The patent modifies the molecular parameters of the quinazoline derivative to optimize its pharmacokinetic properties. Specifically, the compound structure is designed with lipophilic characteristics and appropriate molecular size to enhance blood-brain barrier penetration while maintaining ErbB2 inhibition activity. This parameter optimization resolves the contradiction between achieving reliable ErbB2 inhibition and ensuring sufficient CNS penetrability.
2Reliability
If existing anti-ErbB2 therapy is used, then tumor growth is inhibited, but neuro-cognitive decline occurs due to whole brain radiation therapy
Solution Approach 1:
The quinazoline derivative acts as a selective intermediary agent that targets ErbB2 signaling specifically in the CNS without requiring aggressive radiation therapy. The compound's selective inhibition of ErbB2 in brain metastases provides tumor control while avoiding the neuro-cognitive damage associated with conventional whole brain radiation, thus resolving the contradiction between tumor inhibition and neuro-cognitive preservation.
3Reliability
If EGFR inhibitors are used to treat ErbB2 positive cancer, then ErbB2 activity is reduced, but EGFR-mediated diarrhea and skin rash increase
Solution Approach 1:
The patent achieves local quality selectivity by designing a quinazoline derivative with preferential binding affinity for ErbB2 over EGFR. The molecular structure incorporates specific interaction motifs that favor ErbB2 inhibition while minimizing off-target effects on EGFR. This selective local inhibition resolves the contradiction between reducing ErbB2 activity and avoiding EGFR-mediated toxicities such as diarrhea and skin rash.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present application relates to crystalline forms of (R)-N-(4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-3-methylphenyl)-5-((3,3-difluoro-1-methylpiperidin-4-yl)oxy)-6-methoxyquinazolin-4-amine, methods for the preparation thereof, pharmaceutical compositions comprising one or more of the crystalline forms as an active ingredient, and use of the crystalline forms in the treatment of hyperproliferative diseases.